10:01 AM EST, 11/10/2026 (MT Newswires) -- AstraZeneca (AZN.L, ZN.ST) acquired US-based preclinical biotechnology company Omniose, following a three-year exclusive research collaboration. The transaction strengthens the British drugmaker's vaccine portfolio through Omniose's proprietary bioconjugation platform for conjugate vaccine development, according to a Tuesday release from the acquired company. Omniose will be integrated as a subsidiary under AstraZeneca's Infectious Disease Unit.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.